OMZYTA
Powder and Solvent for Suspension for Injection 1
registration number
50/30.2/0576
What OMZYTA is and what it is used for
OMZYTA is indicated for simultaneous vaccination against measles, mumps and rubella in individuals 12 months of age or older.
dosage
The dose for any age is approximately 0,5 mL administered intramuscularly or subcutaneously, preferably into the outer aspect of the upper arm.
Individuals first vaccinated at 12 months of age or older should be revaccinated at 4 to 6 years of age since increased risk of exposure typically occurs around primary school entry.
Revaccination is intended to seroconvert those who do not respond to the first dose.
how to take
FOR INTRAMUSCULAR OR SUBCUTANEOUS ADMINISTRATION. Do not inject intravascularly.
What OMZYTA contains
When reconstituted as directed, the dose for injection is approximately 0,5 mL and contains not less than 1 000 CCID50 (50 % cell culture infectious dose) of measles virus, 12 500 CCID50 of mumps virus and 1 000 CCID50 of rubella virus.
other ingredients
Sorbitol, sodium phosphate, sucrose, hydrolysed gelatin, recombinant human albumin, foetal bovine serum, other buffer and media ingredients and approximately 25 μg of neomycin.
The product contains no preservative.
Diluent: Water for injection.
Therapeutic classification
A.30.1 Antibodies.